David Westenberg
Stock Analyst at Piper Sandler
(4.69)
# 172
Out of 5,111 analysts
188
Total ratings
60.75%
Success rate
27.39%
Average return
Main Sectors:
Stocks Rated by David Westenberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLLN BillionToOne | Initiates: Overweight | $150 | $96.64 | +55.22% | 1 | Dec 1, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $15 → $19 | $15.76 | +20.56% | 3 | Nov 11, 2025 | |
| TEM Tempus AI | Maintains: Neutral | $105 → $80 | $68.67 | +16.50% | 6 | Nov 11, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Neutral | $1.5 → $2 | $2.12 | -5.66% | 10 | Nov 11, 2025 | |
| NTRA Natera | Maintains: Overweight | $220 → $230 | $228.40 | +0.70% | 17 | Nov 11, 2025 | |
| FLGT Fulgent Genetics | Maintains: Neutral | $21 → $30 | $26.92 | +11.44% | 10 | Nov 11, 2025 | |
| EXAS Exact Sciences | Maintains: Overweight | $70 → $80 | $101.74 | -21.37% | 13 | Nov 11, 2025 | |
| CTKB Cytek Biosciences | Maintains: Overweight | $8 → $7.5 | $4.64 | +61.64% | 10 | Nov 11, 2025 | |
| DGX Quest Diagnostics | Maintains: Neutral | $190 → $200 | $184.11 | +8.63% | 8 | Oct 27, 2025 | |
| GH Guardant Health | Maintains: Overweight | $60 → $90 | $102.67 | -12.34% | 10 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 → $6.5 | $6.85 | -5.11% | 13 | Oct 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $20 | $15.69 | +27.47% | 15 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $140 | $150.61 | -7.04% | 3 | Sep 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $210 → $215 | $120.98 | +77.72% | 15 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $510 → $700 | $700.55 | -0.08% | 11 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $12 → $18 | $21.70 | -17.05% | 10 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $11 | $11.92 | -7.72% | 10 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $190 → $185 | $134.92 | +37.12% | 16 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $260 → $280 | $263.33 | +6.33% | 4 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $29.06 | - | 2 | Jan 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $36.74 | - | 1 | Nov 21, 2017 |
BillionToOne
Dec 1, 2025
Initiates: Overweight
Price Target: $150
Current: $96.64
Upside: +55.22%
10x Genomics
Nov 11, 2025
Maintains: Neutral
Price Target: $15 → $19
Current: $15.76
Upside: +20.56%
Tempus AI
Nov 11, 2025
Maintains: Neutral
Price Target: $105 → $80
Current: $68.67
Upside: +16.50%
Pacific Biosciences of California
Nov 11, 2025
Maintains: Neutral
Price Target: $1.5 → $2
Current: $2.12
Upside: -5.66%
Natera
Nov 11, 2025
Maintains: Overweight
Price Target: $220 → $230
Current: $228.40
Upside: +0.70%
Fulgent Genetics
Nov 11, 2025
Maintains: Neutral
Price Target: $21 → $30
Current: $26.92
Upside: +11.44%
Exact Sciences
Nov 11, 2025
Maintains: Overweight
Price Target: $70 → $80
Current: $101.74
Upside: -21.37%
Cytek Biosciences
Nov 11, 2025
Maintains: Overweight
Price Target: $8 → $7.5
Current: $4.64
Upside: +61.64%
Quest Diagnostics
Oct 27, 2025
Maintains: Neutral
Price Target: $190 → $200
Current: $184.11
Upside: +8.63%
Guardant Health
Oct 22, 2025
Maintains: Overweight
Price Target: $60 → $90
Current: $102.67
Upside: -12.34%
Oct 16, 2025
Reiterates: Neutral
Price Target: $5 → $6.5
Current: $6.85
Upside: -5.11%
Oct 15, 2025
Maintains: Overweight
Price Target: $15 → $20
Current: $15.69
Upside: +27.47%
Sep 11, 2025
Maintains: Overweight
Price Target: $120 → $140
Current: $150.61
Upside: -7.04%
Aug 11, 2025
Maintains: Overweight
Price Target: $210 → $215
Current: $120.98
Upside: +77.72%
Aug 11, 2025
Maintains: Neutral
Price Target: $510 → $700
Current: $700.55
Upside: -0.08%
Aug 11, 2025
Maintains: Neutral
Price Target: $12 → $18
Current: $21.70
Upside: -17.05%
Aug 4, 2025
Maintains: Overweight
Price Target: $12 → $11
Current: $11.92
Upside: -7.72%
May 15, 2025
Maintains: Overweight
Price Target: $190 → $185
Current: $134.92
Upside: +37.12%
May 6, 2025
Maintains: Neutral
Price Target: $260 → $280
Current: $263.33
Upside: +6.33%
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $29.06
Upside: -
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $36.74
Upside: -